INmune Bio Inc. Presents Data On INB03's Role As An Immune Check Point Modulator In The Treatment Of High-Risk Breast Cancer At AACR 2024
Portfolio Pulse from Benzinga Newsdesk
INmune Bio Inc. (NASDAQ:INMB) presented data on INB03, a novel immunotherapy for high-risk breast cancer, at AACR 2024. INB03 targets soluble TNF to modulate immune checkpoints, enhancing therapeutic outcomes in HER2+ and triple-negative breast cancer (TNBC). Studies showed INB03, in combination with anti-HER2 and anti-PD1 therapies, reduced tumor growth and metastasis by altering immune cell behavior and decreasing immune checkpoint proteins. The company seeks partners to advance clinical development and expand its patent portfolio for INB03 in oncology.
April 08, 2024 | 12:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
INmune Bio Inc. presented promising data on INB03, a novel immunotherapy for high-risk breast cancer, at AACR 2024, showing potential in reducing tumor growth and metastasis by targeting soluble TNF.
The positive data presented on INB03's effectiveness in high-risk breast cancer treatment, particularly in HER2+ and TNBC, positions INmune Bio Inc. favorably for potential partnerships and clinical development advancements. The company's focus on expanding its patent portfolio and seeking partners for INB03's further development could lead to increased investor interest and a positive short-term impact on INMB's stock price.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100